This session will cover patients with cancer who frequently require palliative radiation treatment as a component of their care.  Radiotherapy is an effective means of reducing patient distress related to painful bone metastases, neurological compromise from spinal cord compression and brain meta

Seismic changes are rattling the Medicare physician payment world, and radiation oncologists must immediately adapt or face serious payment penalties under the new Quality Payment Program (QPP).

In this session, attendees will review the basics of radiotherapy for sarcoma as well as the selective use of IMRT and IGRT to improve tumor coverage and reduce acute and late complications. 

Indications for radiotherapy and treatment techniques used for several types of head and neck cancer (oropharyngeal, nasopharyngeal, hypopharyngeal, laryngeal, oral cavity, thyroid) will be discussed.

This course will explore management of patients with advanced cancer in the context of a team-based approach to care.  While palliative radiotherapy may at times be less technically complex than other forms of radiotherapy treatments, the accompanying discussions with patients and families is hig

This course will cover the management of gynecologic malignancies, concentrating on cervical (25 minutes), uterine (25 minutes), and vulvar cancers (15 minutes), with time for questions from the audience (15 minutes).  Participants will review the seminal trials and manuscripts which guide curren

In this course, the role of radiation therapy in the management of patients with extranodal non-Hodgkin’s lymphoma of the following sites: CNS, orbit and skin, will be reviewed.

Controversy exists as to the need for surgical staging in all patients. The proper application of adjuvant radiotherapy and chemotherapy also is a source of considerable debate. This educational session will review these controversies with special attention to the impact on patient care.

This session will review and update the current standard of care for pediatric sarcomas including rhabdomyosarcoma, Ewing sarcoma, and other soft tissue sarcomas. Recent and current COG trials will be highlighted.

The specific scenarios will include men with newly diagnosed localized, locally advanced, post-operative pT3,4 and/or margin + disease in the setting of an undetectable PSA in addition to post-operative or post-radiation PSA recurrence.